What determines the cost-effectiveness of diabetes screening?
- 26 April 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 49 (7), 1536-1544
- https://doi.org/10.1007/s00125-006-0248-x
Abstract
The cost-effectiveness of screening for diabetes is unknown but has been modelled previously. None of these models has taken account of uncertainty. We aimed to describe these uncertainties in a model where the outcome was CHD risk.Keywords
This publication has 28 references indexed in Scilit:
- A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99 (1)European Journal of Preventive Cardiology, 2003
- Screening for Type 2 diabetes—should it be now?Diabetic Medicine, 2003
- Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 DiabetesNew England Journal of Medicine, 2003
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screeningInternational Journal of Obesity, 2000
- Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteriaThe Lancet, 1999
- The UK Prospective Diabetes studyThe Lancet, 1998
- The Cost-effectiveness of Screening for Type 2 DiabetesJAMA, 1998
- Prediction of Coronary Heart Disease Using Risk Factor CategoriesCirculation, 1998
- Undiagnosed Glucose Intolerance in the Community: the Isle of Ely Diabetes ProjectDiabetic Medicine, 1995